Imidin N 1

Xylometazoline Hydrochloride, the active ingredient in Imidin N 1, is an alpha‑adrenergic agonist (imidazoline derivative) presented as a nasal spray for topical nasal use. It relieves nasal congestion associated with the common cold, sinusitis and allergic rhinitis in adults and children.

GNH USA supplies Imidin N 1 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Xylometazoline Hydrochloride is a nasal decongestant that acts on the upper‑respiratory tract to reduce swelling. - Nasal congestion due to common cold: provides rapid relief of blockage by constricting nasal mucosal vessels. - Sinusitis‑associated congestion: diminishes edema to improve sinus drainage and breathing. - Allergic rhinitis: lessens nasal swelling caused by allergen‑triggered inflammation.

Adverse reactions may occur following intranasal administration of Xylometazoline Hydrochloride.

Common Side Effects: - Burning or stinging sensation in the nose - Nasal dryness or irritation - Sneezing - Headache - Mild epistaxis (nosebleed)

Serious or Rare Side Effects: - Severe hypertension or tachycardia - Rebound nasal congestion with prolonged use - Allergic reactions such as rash, pruritus, or angioedema - Nasal ulceration or perforation - Persistent nasal bleeding

Before using Imidin N 1, consider the following safety measures. - Contraindicated in patients with known hypersensitivity to xylometazoline or other imidazoline derivatives. - Avoid prolonged use beyond three consecutive days to prevent rebound congestion. - Use with caution in individuals with hypertension, cardiovascular disease, diabetes, or thyroid disorders. - Pregnant or breastfeeding women should consult a healthcare professional before use. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Xylometazoline Hydrochloride may interact with other agents that affect blood pressure or vascular tone.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Systemic sympathomimetic decongestants: additive vasoconstrictive effect.

Moderate Interactions (Monitor Closely): - Antihypertensive medications: possible attenuation of blood‑pressure‑lowering effect. - Tricyclic antidepressants: may enhance vasoconstriction. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): monitor for increased nasal irritation.